Allergan offloads obesity biz for $75M plus milestones; AZ up on broker's advice to shorts;

@FiercePharma: isn't getting post-marketing data on fast-tracked drugs, per JAMA. Required studies undone or unreported. JAMA report | Follow @FiercePharma

@CarlyHFierce: Biogen's Tecfidera drives rosy Q3 results, higher forecast. ICYMI yesterday | Follow @CarlyHFierce

> Allergan ($AGN) agreed to sell its obesity unit to Apollo Endosurgery for $75 million up front, plus a potential $15 million equity interest in the company, plus up to $20 million in milestone payments. Report | FierceMedicalDevices story

> AstraZeneca ($AZN) shares bounced yesterday after Merrill Lynch advised short sellers to close their positions in advance of news on its pipeline drugs; the company reports earnings Thursday. Report

> Hi-Tech Pharmacal settled a class-action lawsuit that claimed its advertising for allergy drug Nasal Ease was misleading. Report

> Brazil's Hypermarcas, a top generics producer in the country, plans to buy back $300 million in bonds to reduce debt. Report

Medical Device News

@FierceMedDev: DOD agency commits $70M to develop brain-monitoring implant. Item | Follow @FierceMedDev

@MarkHFierce: Apollo Endosurgery, a 2012 Fierce 15 winner, aims for big growth by snatching up Allergan's obesity device business. Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: A blog post from the FDA late last week highlighted the agency's efforts to regulate nanotechnology. Blog | Follow @MichaelGFierce

> St. Jude Medical touts positive preliminary results for Portico heart valve. Article

> Edwards slips as so-so outlook leaves investors underwhelmed. Report

> Covidien flips surgical sealants to Integra for $235M. More

Biotech News

@FierceBiotech: Popular on FierceCRO.com: InVentiv opens U.K. hub as EU demand climbs. Article | Follow @FierceBiotech

@JohnCFierce: The ax drops at troubled Merck as big restructuring gets underway. Story | Follow @JohnCFierce

@DamianFierce: Ex-Calistoga chief Gallagher joins VC Frazier Healthcare to steer biotech bets. News | Follow @DamianFierce

> Sanofi, Glaxo sign up for vaccine R&D projects under new Gates initiative. Story

> Calithera grabs $35M round to fund first slate of cancer drug studies. More

> Eli Lilly partners with Pfizer on its high-risk PhIII pain med tanezumab. News

Pharma Manufacturing News

@EricPFierce: What drugs are up for grabs by generic makers next year? Here's the FiercePharma list of 2014 patent losses. | Follow @EricPFierce

> Wockhardt profits crater after U.S., U.K. plant bans. More

> Manufacturing glitch leaves Novo insulin cartridges with bad fills. Report

> Gilead expanding facility that makes highly anticipated hep C drug. Story

> India's plan to inspect China plants stalled. Article

Biotech Research News

@EmilyMFierce: I took a look at 5 promising preclinical drug programs across industry/academia for this latest report. Feature | Follow @EmilyMFierce

> Fast-acting antidepressants discovered. Report

> New obstacle found in search for HIV/AIDS cure. Item

> Certain microRNAs might be viable Alzheimer's targets. Article

> CytomX 'probody' kills pancreatic cancer cells, leaves healthy tissue intact. Story

And Finally... In almost every European country, bikes are outselling new cars. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.